MarkChristopherMarkowskiMD
Oncology • Washington, DCInstructor, Medicine, Johns Hopkins University School of Medicine
Are you Dr. Markowski?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 88 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
5255 Loughboro Road NW
Washington, DC 20016Phone+1 202-660-6500Fax+1 202-660-6501- Is this information wrong?
Summary
- Dr. Mark Markowski, MD is an oncologist in Washington, District of Columbia. He is currently licensed to practice medicine in District of Columbia, Virginia, and Pennsylvania. He is affiliated with Sibley Memorial Hospital, Johns Hopkins Hospital, and Johns Hopkins Bayview Medical Center.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2013 - 2016
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2009 - 2012
Georgetown University School of MedicineClass of 2009
Certifications & Licensure
MD State Medical License 2012 - 2025
DC State Medical License 2015 - 2024
VA State Medical License 2022 - 2024
PA State Medical License 2020 - 2022
NY State Medical License 2011 - 2013
Clinical Trials
- Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations Start of enrollment: 2018 Sep 10
- COMbination of Bipolar Androgen Therapy and Nivolumab Start of enrollment: 2018 Sep 05
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations Start of enrollment: 2019 Jun 03
- Join now to see all
Publications & Presentations
PubMed
- Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.Lalji, A., Mark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A Carducci, Channing J Pall...> ;Nature Communications. 2024 Jan 2
- 1 citationsPredicting Prostate Cancer Molecular Subtype With Deep Learning on Histopathologic Images.Eric Erak, Lia DePaula Oliveira, Adrianna A Mendes, Oluwademilade Dairo, Onur Ertunc, Ibrahim Kulac, Javier A Baena-Del Valle, Tracy Jones, Jessica L Hicks, Stephanie ...> ;Modern Pathology. 2023 Oct 1
- Test-retest repeatability of organ uptake on PSMA-targetedF-DCFPyL PET/CT in patients with prostate cancer.Rudolf A Werner, Susanne Lütje, Bilêl Habacha, Lena Bundschuh, Takahiro Higuchi, Andreas K Buck, Aleksander Kosmala, Constantin Lapa, Markus Essler, Martin A Lodge, Ke...> ;The Prostate. 2023 Sep 1
- Join now to see all
Press Mentions
Veru Announces Positive Phase 1b/2 Clinical Study Update for Sabizabulin (VERU-111) in Men with Metastatic Castration Resistant Prostate Cancer Presented at the 2021 ASCO Annual MeetingJune 7th, 2021- COMBAT-CRPC Points to Potential of Combining BAT, NivolumabMay 6th, 2021
- Veru Expands Oncology Drug Pipeline; Exclusively Licenses Phase 3 Clinical Stage Targeted Therapy for Endocrine Resistant Metastatic Breast CancerDecember 9th, 2020
- Join now to see all
Hospital Affiliations
Johns Hopkins Bayview Medical CenterBaltimore, Maryland
Johns Hopkins HospitalBaltimore, Maryland
Sibley Memorial HospitalWashington, District of Columbia
